Michael Boland, MD
Ophthalmology · Boston, MANPI 1023074143
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,983 of the $80,630 with a category attached, or 85.6%. 8 manufacturers reported payments, led by Topcon Healthcare, Inc. at 42.3% of the total. Reporting peaked in 2022 at $45,621 and has fallen 94.2% since, to $2,627 in 2025. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $1875.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Topcon Healthcare, Inc.$34K
- Carl Zeiss Meditec, Inc.$31K
- AbbVie$11K
- Janssen Research & Development, LLC$4K
- Carl Zeiss Meditec USA, Inc.$123
- Alcon$19
- plus $27 from 2 others
What the payments were for
- Consulting fees$68,98386%
- Speaking & faculty fees$9,42512%
- Travel & lodging$1,5032%
- Food & beverage$7191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Topcon Healthcare, Inc. | 7 | $34,106 |
| Carl Zeiss Meditec, Inc. | 18 | $31,230 |
| AbbVie(2 entities) | 13 | $10,900 |
| Janssen Research & Development, LLC | 1 | $4,225 |
| Carl Zeiss Meditec USA, Inc. | 1 | $123 |
| Alcon | 1 | $19 |
| Ivantis, Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HARMONY$30,000
- CIRRUS HD-OCT$23,199
- Humphrey HFA$17,269
- FORUM$15,484
- FORUM Glaucoma Workplace$10,407
- Retina Workplace$9,220
- DURYSTA$8,022
- CLARUS 500$6,500
- Glaucoma Workplace$6,500
- Humphrey Field Analyzer (HFA3)$5,780
- CLARUS$4,670
- CIRRUS 6000$3,250
- IOLMaster 700$2,720
- VisuMax$2,720
- OCT TRITON$2,500
- PLEX Elite 9000$2,275
- QUATERA 700$1,360
How this compares
$80,630 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 192 | $9,426 |
| VyzultaLatanoprostene Bunod | 17 | $7,571 |
| RhopressaNetarsudil Mesylate | 13 | $7,007 |
| Latanoprost | 566 | $6,358 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 247 | $4,375 |
| LumiganBimatoprost | 11 | $4,274 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 22 | $4,042 |
| Brimonidine Tartrate | 221 | $3,772 |
| Timolol Maleate | 165 | $3,350 |
| Travoprost | 13 | $3,321 |
| Dorzolamide Hcl | 66 | $1,445 |
| Acetazolamide ErAcetazolamide | 20 | $650 |
| Atropine Sulfate | 11 | $342 |
| Ketorolac Tromethamine | 14 | $311 |
| Ofloxacin | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $10,900 | $4,27411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.